Aibotics Inc. (AIBT) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Aibotics Inc. (AIBT) trades at $0.0004 with AI Score 45/100 (Grade C). Aibotics Inc. focuses on psychedelic methodologies for mental health treatment in the United States. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for AIBT: AIBT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AIBT against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
AIBT: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Aibotics Inc. (AIBT) Healthcare & Pipeline Overview
Aibotics Inc. is a biotechnology company focused on psychedelic methodologies for treating mental health issues such as palliative care, depression, and anxiety in the United States. Formerly Mycotopia Therapies, the company rebranded in February 2025 and is based in Miami, Florida, operating with a negative profit margin.
What Is the Investment Thesis for AIBT?
Investing in Aibotics Inc. presents a high-risk, high-reward opportunity in the emerging field of psychedelic medicine. The company's focus on developing treatments for mental health conditions such as palliative care, depression, and anxiety aligns with a growing recognition of the therapeutic potential of psychedelics. However, Aibotics operates in a highly regulated and competitive industry, and its financial performance is currently characterized by a negative profit margin of -314.5%. Key growth catalysts include the potential for regulatory approvals of psychedelic-assisted therapies and the expansion of clinical trials to demonstrate the efficacy of Aibotics' methodologies. The company's success will depend on its ability to navigate the complex regulatory landscape, secure funding for research and development, and establish strategic partnerships with healthcare providers and research institutions. The high beta of 1.71 indicates significant volatility, reflecting the speculative nature of the investment.
Based on FMP financials and quantitative analysis
AIBT Key Highlights
Aibotics Inc. operates in the biotechnology sector, focusing on psychedelic methodologies for mental health treatment.
- The company's research targets palliative care, depression, and anxiety, addressing significant unmet needs in mental healthcare.
- Aibotics Inc. rebranded from Mycotopia Therapies in February 2025, signaling a strategic shift.
- The company is based in Miami, Florida, positioning it within a growing hub for healthcare innovation.
- Aibotics Inc. has a negative profit margin of -314.5%, reflecting its early-stage development and investment in research.
Who Are AIBT's Competitors?
AIBT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AIBT's Key Strengths?
Focus on the emerging field of psychedelic medicine.
- Proprietary psychedelic methodologies.
- Potential for innovative treatments for mental health disorders.
- Experienced leadership team.
What Are AIBT's Weaknesses?
Negative profit margin.
- Limited operating history.
- Dependence on regulatory approvals.
- High competition in the biotechnology industry.
What Could Drive AIBT Stock Higher?
Results from ongoing clinical trials evaluating the efficacy of Aibotics' psychedelic methodologies.
- Potential regulatory approvals for psychedelic-assisted therapies.
- Expansion of research and development activities to explore new therapeutic applications of psychedelics.
- Strategic partnerships with pharmaceutical companies and research institutions.
- Increasing awareness and acceptance of psychedelic medicine.
What Are the Key Risks for AIBT?
Financial-distress signal — its Altman Z-Score of -46.40 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles and delays in obtaining approvals for psychedelic-based therapies.
- Competition from established pharmaceutical companies and other biotech firms.
- Negative public perception of psychedelics and concerns about their safety and efficacy.
- Uncertainty surrounding the long-term effects of psychedelic therapies.
- Financial risks associated with operating in a highly regulated and capital-intensive industry.
What Are the Growth Opportunities for AIBT?
- Expansion of Clinical Trials: Aibotics has the opportunity to expand its clinical trials to further validate the efficacy of its psychedelic methodologies. Positive results from these trials could lead to regulatory approvals and increased adoption by healthcare providers. The global market for clinical trial services is projected to reach $68.9 billion by 2028, providing a substantial opportunity for Aibotics to generate revenue through research and development activities. The timeline for this growth opportunity is dependent on securing funding and navigating the regulatory approval process.
- Strategic Partnerships: Forming strategic partnerships with established pharmaceutical companies and research institutions could accelerate Aibotics' growth and expand its market reach. These partnerships could provide access to funding, expertise, and distribution channels. The pharmaceutical industry is increasingly open to collaborations with smaller biotech companies to access innovative technologies and therapies. This growth opportunity is contingent on Aibotics' ability to demonstrate the value of its psychedelic methodologies and attract potential partners.
- Regulatory Approvals: Securing regulatory approvals for its psychedelic-based therapies is a critical growth opportunity for Aibotics. The regulatory landscape for psychedelics is evolving, with increasing acceptance of their therapeutic potential. Obtaining approvals from regulatory agencies such as the FDA could open up significant market opportunities and establish Aibotics as a leader in the field. The timeline for this growth opportunity is uncertain, as it depends on the results of clinical trials and the evolving regulatory environment.
- Development of Novel Delivery Methods: Aibotics can explore novel delivery methods for its psychedelic therapies to improve patient outcomes and enhance the therapeutic experience. This could include developing formulations that optimize bioavailability, reduce side effects, and provide more precise dosing. The market for drug delivery technologies is projected to grow to $27.4 billion by 2027, driven by the increasing demand for more effective and patient-friendly drug delivery systems. This growth opportunity requires investment in research and development and collaboration with experts in drug delivery technologies.
- Expansion into New Therapeutic Areas: Aibotics can expand its focus beyond palliative care, depression, and anxiety to explore the potential of psychedelics in treating other mental health conditions, such as PTSD, addiction, and eating disorders. This would broaden the company's market reach and diversify its revenue streams. The market for mental health treatments is vast and growing, with significant unmet needs across a range of conditions. This growth opportunity requires further research and development to identify and validate the therapeutic potential of psychedelics in these new areas.
What Are AIBT's Competitive Advantages?
- Proprietary psychedelic methodologies.
- Early mover advantage in the emerging field of psychedelic medicine.
- Focus on specific mental health conditions with unmet needs.
- Potential for intellectual property protection through patents and trade secrets.
What Does AIBT Do?
Aibotics Inc., formerly known as Mycotopia Therapies, is a biotechnology company dedicated to the research and development of psychedelic methodologies for treating mental health disorders. Founded with the vision of providing innovative solutions for conditions like palliative care, depression, and anxiety, the company officially changed its name to Aibotics Inc. in February 2025, signaling a strategic shift in its approach to mental health treatment. Based in Miami, Florida, Aibotics operates primarily within the United States, focusing on the burgeoning field of psychedelic-assisted therapy. The company's core activities revolve around studying the therapeutic potential of psychedelic compounds and developing methodologies for their safe and effective use in clinical settings. Aibotics aims to address the unmet needs of patients suffering from mental health conditions by pioneering novel treatment options that leverage the unique properties of psychedelics. While still in its early stages, Aibotics is actively engaged in research and development efforts to advance its pipeline of psychedelic-based therapies. The company's focus on palliative care, depression, and anxiety reflects a commitment to addressing some of the most pressing mental health challenges facing society today. As the regulatory landscape surrounding psychedelics evolves, Aibotics seeks to position itself as a leader in the development and commercialization of innovative treatments that can improve the lives of patients in need.
What Products and Services Does AIBT Offer?
- Studies psychedelics for mental health treatment.
- Develops psychedelic methodologies for palliative care.
- Creates psychedelic methodologies for depression.
- Creates psychedelic methodologies for anxiety.
- Researches novel therapies for mental health disorders.
- Aims to provide innovative solutions for mental health conditions.
- Focuses on the therapeutic potential of psychedelic compounds.
How Does AIBT Make Money?
- Research and development of psychedelic-based therapies.
- Conducting clinical trials to evaluate the efficacy of its methodologies.
- Seeking regulatory approvals for its therapies.
- Potential commercialization of approved therapies through partnerships or direct sales.
What Industry Does AIBT Operate In?
Aibotics Inc. operates within the rapidly evolving biotechnology industry, specifically targeting the emerging field of psychedelic medicine. The market for mental health treatments is substantial, with increasing recognition of the limitations of existing therapies and growing interest in alternative approaches. The competitive landscape includes companies like CKNTF (Cyknos Therapeutics Inc.) and MRVT (Murrieta Genomics Inc.), which are also exploring innovative solutions for healthcare challenges. The industry is characterized by high regulatory hurdles, significant research and development costs, and intense competition for funding and market share. As of 2026, the psychedelic medicine market is still nascent, but projections suggest substantial growth as regulatory barriers are reduced and clinical evidence accumulates.
Who Are AIBT's Key Customers?
- Patients suffering from palliative care needs.
- Patients suffering from depression.
- Patients suffering from anxiety.
- Healthcare providers seeking innovative treatment options.
Company Profile
Aibotics Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Miami, US. The company is led by CEO Benjamin Kaplan. AIBT has traded publicly since 2006.
How Aibotics Inc. Is Valued
Relative to its peer group, AIBT's quantitative score of 45/100 is below the peer average of 76/100.
Key Financial Metrics
Return on equity for Aibotics Inc. stands at 55.8%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.06 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Aibotics Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -46.40 places it in the distress zone, a signal of elevated financial risk.
AIBT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Aibotics' future, indicating that those closest to the company believe in its growth potential.
- Community sentiment has shifted positively, with discussions highlighting innovative product developments that could capture market share.
- Analysts have noted strong interest from institutional investors, which often reflects a robust outlook on the company's fundamentals.
- Recent partnerships in the tech sector have enhanced Aibotics' credibility and visibility, fostering optimism among investors.
Bear Case
- Some analysts express concerns over the company's ability to scale operations effectively, which could hinder growth prospects.
- Recent social sentiment shows skepticism regarding the sustainability of Aibotics' current business model amidst increasing competition.
- Community discussions have raised red flags about potential regulatory challenges that could impact the company's operations.
- A lack of consistent revenue growth over the past quarters has led to hesitation among some investors, feeding a bearish outlook.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
AIBT Latest News
No recent news available for AIBT.
AIBT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AIBT.
Price Targets
Wall Street price target analysis for AIBT.
AIBT MoonshotScore
What does this score mean?
The MoonshotScore rates AIBT 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Benjamin Kaplan
CEO
Benjamin Kaplan serves as the Chief Executive Officer of Aibotics Inc. His background includes experience in the healthcare and biotechnology sectors, with a focus on identifying and developing innovative therapies for unmet medical needs. Kaplan's expertise lies in strategic planning, business development, and capital raising. He has a proven track record of building and scaling companies in the healthcare industry.
Track Record: Since assuming the role of CEO, Benjamin Kaplan has focused on rebranding the company and shifting its strategic focus towards psychedelic methodologies. Key milestones under his leadership include initiating clinical trials and securing partnerships with research institutions. Kaplan's leadership is aimed at positioning Aibotics as a leader in the emerging field of psychedelic medicine.
AIBT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Aibotics Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited trading volume and may be subject to greater price volatility. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and the potential for fraud or manipulation. These companies are not required to be SEC reporting companies.
- OTC Tier: OTC Other
- Limited regulatory oversight.
- Potential for fraud or manipulation.
- Lack of financial transparency.
- Limited liquidity.
- High price volatility.
- Verify the company's registration and legal status.
- Review the company's financial statements, if available.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Evaluate the company's risk factors and potential liabilities.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Company's focus on psychedelic methodologies for mental health treatment.
- Rebranding and strategic shift towards psychedelic medicine.
- Initiation of clinical trials.
- Partnerships with research institutions.
Common Questions About AIBT (Healthcare)
What does the AI Score mean for AIBT?
AIBT holds an AI Score of 45/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Aibotics Inc. focuses on psychedelic methodologies for mental health treatment in the United States. The company researches treatments for palliative care, depression, and anxiety, operating in …
What does Aibotics Inc. do?
Aibotics Inc. is a biotechnology company focused on the research and development of psychedelic methodologies for treating mental health disorders. The company's primary focus is on developing innovative treatments for palliative care, depression, and anxiety. Aibotics conducts clinical trials to evaluate the efficacy of its therapies and seeks regulatory approvals to commercialize its products.
What do analysts say about AIBT stock?
As of March 16, 2026, there is limited analyst coverage of AIBT stock due to its OTC listing and early stage of development. Key valuation metrics such as P/E ratio (-0.09) and profit margin (-314.5%) reflect the company's current financial challenges. Growth considerations include the potential for regulatory approvals and the expansion of clinical trials.
What are the main risks for AIBT?
The main risks for Aibotics Inc. include regulatory hurdles, competition from established pharmaceutical companies, negative public perception of psychedelics, uncertainty surrounding the long-term effects of psychedelic therapies, and financial risks associated with operating in a capital-intensive industry. The company's reliance on regulatory approvals makes it vulnerable to delays and setbacks.
What are the key factors to evaluate for AIBT?
Aibotics Inc. (AIBT) holds an AI score of 45/100 (low). Investing in Aibotics Inc. presents a high-risk, high-reward opportunity in the emerging field of psychedelic medicine. Not financial advice.
How frequently does AIBT data refresh on this page?
AIBT's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven AIBT's recent stock price performance?
Aibotics Inc. (AIBT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on the emerging field of psychedelic medicine. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AIBT overvalued or undervalued right now?
Aibotics Inc. (AIBT) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research AIBT before investing?
Before investing in Aibotics Inc. (AIBT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on Aibotics Inc. due to its OTC listing and early stage of development.
- Financial data is limited and may not be representative of future performance.
- The psychedelic medicine industry is subject to significant regulatory uncertainty.